EntreMed ENMD-2076 Phase 1 Data in Hematological Studies to be Presented at ASH

ENMD-2076 Multiple Myeloma and Leukemia Abstracts to be Published in Blood

ROCKVILLE, Md., Nov. 9, 2010 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, today announced presentations for its Phase 2 oncology drug candidate, ENMD-2076.  Data for the ENMD-2076 Phase 1 studies in multiple myeloma and leukemia will be presented by EntreMed investigators at the 2010 Annual Meeting of the American Society of Hematology (ASH) to be held December 4-7 at the Orange County Convention Center in Orlando, Florida.  Both abstracts were accepted for poster presentation at the meeting and will be published in the print and online November 19, 2010 supplemental volume of Blood.  

(Logo: http://photos.prnewswire.com/prnh/20010620/ENMDLOGO )

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

The Phase 1 data will be presented as listed below.

  • Poster Session : Myeloma – Therapy, excluding transplantation: Poster I; Saturday, December 4, 20109:00 a.m.7:30 p.m. (author presentation time 5:30 – 7:30 p.m.); Hall A3/A4, Board No. I-937; Title: "Clinical activity of a novel multiple tyrosine kinase and Aurora kinase inhibitor, ENMD-2076, against multiple myeloma: interim Phase 1 trial results."

  • Poster Session : Acute myeloid leukemia – Therapy, excluding transplantation: Poster III; Monday, December 6, 201010:00 a.m.8:00 p.m. (author presentation time 6:00 – 8:00 p.m.); Hall A3/A4, Board No. III-86; Title: "A Phase 1 study of ENMD-2076 in patients with relapsed or refractory leukemia."

About ENMD-2076

ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action. Preclinical studies with ENMD-2076 demonstrated significant antitumor activity, including tumor regression, in multiple solid and hematological malignancies. ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase. Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers. ENMD-2076 also targets the  VEGFR, Flt-3 and FGFR3 kinases which have been shown to play important roles in the pathology of several cancers. While ENMD-2076 is currently in a Phase 2 trial in ovarian cancer, preclinical and clinical activities are ongoing in assessing the compound's applicability in other forms of cancer.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company committed to developing ENMD-2076, a selective angiogenic kinase inhibitor, for the treatment of cancer.  ENMD-2076 is currently in a multi-center Phase 2 study in ovarian cancer and in several Phase 1 studies in solid tumors, multiple myeloma, and leukemia.  Additional information about EntreMed is available on the Company's web site at www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time.  Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including  the risk that we may be unable to continue as a going concern as a result of our inability to raise sufficient capital for our operational needs; the possibility that we may be delisted from trading on the Nasdaq Capital Market; the volatility of our common stock; risks relating to the need for additional capital and the uncertainty of securing additional funding on favorable terms; the failure to consummate a transaction to monetize the royalty stream for any reason, including our inability to obtain the required third-party consents; declines in actual sales of Thalomid® resulting in reduced revenues; risks associated with the Company's product candidates; the early-stage products under development; results in preclinical models are not necessarily indicative of clinical results; uncertainties relating to preclinical and clinical trials, including delays to the commencement of such trials; success in the clinical development of any products; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks). 

Contact:

 

Ginny Dunn

 

Associate Director

 

Corporate Communications & Investor Relations

 

240-864-2643

 
 


 

SOURCE EntreMed

CONTACT: Ginny Dunn, Associate Director, Corporate Communications & Investor Relations, +1-240-864-2643
 

Web Site: http://www.entremed.com
 

Posted: November 2010

View comments

Hide
(web4)